Thermo Fisher Scientific Inc. $TMO Shares Acquired by Andra AP fonden

Andra AP fonden increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 72,457 shares of the medical research company’s stock after purchasing an additional 14,643 shares during the quarter. Andra AP fonden’s holdings in Thermo Fisher Scientific were worth $36,327,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Kilter Group LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Legacy Wealth Managment LLC ID boosted its stake in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. Core Wealth Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $30,000. Allied Private Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $26,000. Finally, MBM Wealth Consultants LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Goldman Sachs raised its price target on TMO to $780 from $650 and maintained a Buy rating. The significantly higher target reinforces the view that Thermo Fisher’s earnings momentum and long-term growth prospects justify additional upside. Goldman Sachs Adjusts Price Target on Thermo Fisher Scientific
• Positive Sentiment: Thermo Fisher is partnering with Mayo Clinic on Precure, an initiative designed to generate population-scale molecular data. The project could support future diagnostics, therapies and other healthcare products while strengthening TMO’s position in genomics, multi-omics and data-enabled medicine. Ultima Genomics was selected to provide sequencing technology for the one-million-sample dataset. Mayo Clinic and Thermo Fisher Partner to Create Precure
• Positive Sentiment: Industry reports point to expanding markets relevant to Thermo Fisher. ADME-toxicology testing, high-content screening, drug-discovery informatics and automated cell-therapy processing are forecast to grow substantially through the end of the decade. These reports are not new contracts or guidance changes, but they support the long-term demand outlook for TMO’s research and bioprocessing businesses. ADME-Toxicology Testing Market Report
• Neutral Sentiment: Although TMO recently outperformed over six months on strong quarterly results, it has still lagged the broader market in the latest session. The stock’s elevated valuation makes further gains increasingly dependent on sustained earnings growth. Thermo Fisher Stock Rises but Underperforms Market
• Negative Sentiment: A commentary titled “3 Reasons to Sell TMO” warns that the recent rally may have reduced the stock’s margin of safety, increasing downside risk if growth slows or expectations are missed. This is an opinion piece rather than a change in company fundamentals. 3 Reasons to Sell TMO

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday, September 9th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Finally, Scotiabank assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $624.64.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.3%

NYSE:TMO traded up $1.98 during trading hours on Tuesday, reaching $660.74. 733,256 shares of the stock were exchanged, compared to its average volume of 2,251,833. The company has a market capitalization of $244.31 billion, a price-to-earnings ratio of 35.56, a PEG ratio of 2.72 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business has a 50-day moving average of $595.41 and a two-hundred day moving average of $524.10. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $663.57.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.